Celltrion today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions and recommended marketing authorisations ...

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...

In the latest trial of 251 patients, 2.1% discontinued treatment due to adverse events, compared with 6.3% in a RoActemra group. Serious adverse events occurred in 0.5% of vobarilizumab patients ...